D. Pouessel

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study

R.J. Motzer, L. Albiges, S.A.Treviño Aguirre, R. Kanesvaran et autres

BACKGROUND: Primary results from COSMIC-313 demonstrated significantly longer progression-free survival (PFS) with first-line cabozantinib plus nivolumab and ipilimumab versus placebo plus nivolumab and ipilimumab in patients with advanced renal cell carcinoma. Final efficacy and safety results, as well as data from exploratory …

us, fr, mx, sg, pl, ar, it, es, ch, gb (code pays fourni par la source)

3109eP Avelumab first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC) in France: Conditional survival and long-term safety in patients (pts) treated for ≥1 or ≥2 yrs in the AVENANCE real-world study

Philippe Barthélémy, Y. Loriot, C. Thibault, A. Flechon et autres

fr, de (code pays fourni par la source)

3111eP Real-world (RW) use of enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial cancer (Ia/mUC) previously treated with chemotherapy and immunotherapy in France

A. Flechon, D. Pouessel, M. Vuillet, Andrew Brennan et autres

fr, gb, nl (code pays fourni par la source)

35 (PB023): A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF301)

A. Zhang, V. Boni, Adrienne R. Hanson, Claudia La Mantia et autres

1977P Efficacy of talazoparib and avelumab as a maintenance treatment in patients with advanced/metastatic urothelial carcinoma (mUC) whose disease did not progress after a first-line platinum-based chemotherapy (PBCT): The GETUG-TALASUR trial

Elodie Coquan, Elouen Boughalem, D. Pouessel, Justine Lequesne et autres

fr, lu (code pays fourni par la source)

1757P Preliminary results from AVENANCE, an ongoing, noninterventional real-world, ambispective study of avelumab first-line (1L) maintenance treatment in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC)

P. Barthelemy, C. Thibault, Eric Voog, J-C. Eymard et autres

fr, de (code pays fourni par la source)